查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1871026

按產品類型、技術、最終用戶、應用、分銷通路和材質分類的氧合器市場－2025年至2032年全球預測

Artificial Lung Market by Product Type, Technology, End User, Application, Distribution Channel, Material Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，人工肺市場規模將達到 152.4 億美元，複合年成長率為 9.02%。

關鍵市場統計數據
基準年 2024 76.3億美元
預計年份：2025年 83.3億美元
預測年份 2032 152.4億美元
複合年成長率 (%) 9.02%

全面介紹不斷發展的人工肺領域，將設備工程的進步與不斷變化的臨床實踐和應用需求聯繫起來。

人工肺領域正迅速發展成熟，這得益於加護治療創新和先進生物材料工程的融合。推動這項發展的主要因素是臨床上對人工呼吸器替代方案的迫切需求，以及對改善嚴重呼吸衰竭患者預後的迫切願望。新興的設備架構旨在以更高的生物相容性和便攜性來模擬肺部氣體交換，同時治療流程也在不斷調整，以便更早將體外支持納入治療路徑。隨著人們的關注點從急性住院治療轉向門診和居家支持，研發人員和醫療服務提供者必須在加護治療級別的性能、以用戶為中心的設計以及長期安全性之間取得平衡。

材料技術的創新、支撐系統的微型化以及醫療保健服務模式的改變，共同重新定義了人工肺的採用和整合軌跡。

隨著臨床團隊尋求能夠提供穩定氣體交換並最大限度地減少血栓形成和發炎反應的設備，人工肺技術的研發和應用正經歷著變革性的轉變。膜材料的創新正以高性能陶瓷和工程化中空纖維取代傳統聚合物，從而提升了耐用性和血液相容性。同時，驅動主機的小型化和血流動力學管理演算法的改進，使得更靈活的部署模式成為可能，包括攜帶式體外裝置以及用於長期支援的植入裝置。

評估 2025 年實施的進口關稅提高對供應鏈韌性、籌資策略和產品開發時間表的結構性和營運性影響。

2025年實施的新關稅制度和貿易措施為氧合器生產和分銷的整個供應鏈帶來了明顯的摩擦。關鍵進口零件（例如精密泵浦、特種膜和生物相容性聚合物）的關稅提高，增加了依賴跨境採購的組裝的到岸成本。因此，採購團隊和生產負責人正在重新評估供應商集中度、避險策略和合約條款，以維持利潤率和供應的連續性。

將產品架構、膜技術、終端用戶工作流程、應用場景、分銷方式和材料選擇與商業化策略聯繫起來的實用細分洞察

要了解人工肺領域價值創造的組成，需要深入了解產品、技術、終端用戶、應用、分銷管道和材料類型的詳細情形。產品差異化涵蓋體外膜氧合（ECMO）系統和正在研發中的植入式氧合器，其中ECMO系統又可進一步細分為插管、主機、氧合器和泵，這些部件共同決定了手術的複雜性和面積。技術選擇範圍廣泛，從陶瓷膜和平板膜到中空纖維膜，中空纖維膜中聚醚碸和聚丙烯的不同混合物決定了其在滲透性、耐久性和血液相容性方面的權衡。

區域策略挑戰包括協調監管差異、臨床基礎設施和製造地，以加速人工肺技術在全球市場的普及。

區域趨勢正對美洲、歐洲、中東和非洲以及亞太地區的監管預期、報銷機制和生產物流產生深遠影響。在美洲，臨床研究網路和加護治療基礎設施為先進的體外療法提供了支持，但市場准入和規模化發展需要應對不同的支付方體系和醫院採購通訊協定。同時，歐洲、中東和非洲地區的法規環境十分複雜，各國在協調統一的同時，也存在著各自不同的評估標準和採購規範，這共同決定了實施時間表和臨床證據要求。

實現永續差異化的主要企業模式和競爭要務：- 優先發展膜技術創新 - 更嚴格的生產流程 - 建立臨床證據 - 整合銷售管道

人工肺領域的競爭由成熟的醫療設備製造商、專業組件供應商以及將轉化研究成果轉化為商業原型產品的臨床創新者共同推動。領先企業透過在膜科學、泵浦效率和整合感測器系統方面的投資，在性能、易用性和生命週期成本方面實現差異化競爭。設備原始設備製造商 (OEM) 與材料專家之間的策略聯盟日益普遍，從而能夠共同開發膜結構和血液相容性塗層，以減少血栓形成和發炎反應。

針對如何整合模組化設計、供應商多元化、臨床證據項目和客製化商業模式以推動應用和增強韌性，提出具有重大影響力的領導建議

產業領導者應推行一項綜合性議程，同時兼顧技術複雜性、供應鏈韌性和臨床應用路徑。優先採用模組化設備架構可以加快替代供應商的資格認證，並支援迭代式產品更新，而無需進行平台範圍的重新設計。對膜和塗層技術的投資應與嚴格的血液相容性測試和人體工學設計相結合，以減少不利事件並簡化臨床醫生的工作流程。在供應鏈方面，組件採購多元化並考慮區域性製造地可以縮短關鍵組件的前置作業時間，同時降低關稅風險和物流中斷的影響。

一種透明、以證據為導向的調查方法，整合了臨床醫生訪談、材料和設備分析、供應鏈圖譜繪製以及情境測試，以支持策略決策。

我們的研究途徑結合了多方面的證據基礎、定性專家訪談和結構化分析，以全面了解氧合器的現狀。主要研究內容包括與臨床醫生、生物醫學工程師、監管顧問和採購專業人員的討論，以了解臨床工作流程、設備性能優先事項以及實際應用中的障礙。輔助研究涵蓋同儕審查文獻、監管指導文件、專利和製造商技術規範，以驗證技術趨勢和材料科學的進步。設備架構和供應鏈佈局的比較分析有助於評估可製造性和物流風險。

這是一項綜合性研究，它結合了突破性的材料科學、設備便攜性、監管完整性和供應鏈韌性，為臨床應用和商業化規劃了一條切實可行的路徑。

總之，膜材料的進步、設備的微型化以及系統整合度的提高，共同促成了氧合器技術的轉折點，將影響臨床實踐、供應鏈設計和商業化策略。從僅限醫院使用到門診治療以及潛在的植入式應用，需要一種綜合性的方法，將技術創新與臨床醫生的工作流程、監管合規性和支付方的價值評估相結合。關稅趨勢和區域製造的考量進一步凸顯了穩健的採購管道和貼近市場的生產模式的必要性。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 將穿戴式體外膜氧合系統整合到居家醫療環境中
  • 用於個人化人工肺治療的3D列印肺泡支架的進展
  • 開發用於長期人工肺移植的生物相容性聚合物薄膜
  • 採用模組化人工肺裝置支持患有慢性呼吸衰竭的兒童患者
  • 攜帶式氧合器系統的出現已在門診病人臨床試驗中得到驗證
  • 突破性療法認定下的氧合肺裝置快速核准監管途徑
  • 透過生物技術公司和學術機構合作創建的生物工程肺組織構建體

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 依產品類型分類的氧合器市場

  • 體外膜氧合系統
    • 套管
    • 主機
    • 氧合設備
    • 泵浦
  • 植入式氧合器

第9章 人工肺市場：依技術分類

  • 陶瓷膜
  • 平面膜
  • 中空纖維膜
    • 聚醚碸
    • 聚丙烯

第10章 依最終用戶分類的氧合器市場

  • 門診治療中心
  • 居家醫療
  • 醫院

第11章 人工肺市場：依應用領域分類

  • 加護治療
  • 緊急運輸
  • 呼吸輔助

第12章 按分銷通路分類的氧合器市場

  • 直銷
    • 診所帳戶
    • 醫院帳戶
  • 經銷商網路
    • 醫療設備批發商
    • 藥品批發商
  • 線上平台

第13章 依材料類型分類的氧合器市場

  • 聚醚碸
  • 聚丙烯
  • 矽酮

第14章 人工肺市場：依地區分類

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 依組別分類的氧合器市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國氧合器市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Getinge AB
    • LivaNova PLC
    • Medtronic PLC
    • Terumo Corporation
    • Fresenius Medical Care AG & Co. KGaA
    • MC3 Cardiopulmonary Support Inc.
    • SynCardia Systems, LLC
    • ALung Technologies, Inc.
    • Aeson Cardiovascular AG
    • Hemovent GmbH
Product Code: MRR-1A1A064C0598

The Artificial Lung Market is projected to grow by USD 15.24 billion at a CAGR of 9.02% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 7.63 billion
Estimated Year [2025] USD 8.33 billion
Forecast Year [2032] USD 15.24 billion
CAGR (%) 9.02%

An integrative introduction to the evolving artificial lung landscape that connects advances in device engineering with shifting clinical practices and adoption imperatives

The artificial lung arena is rapidly maturing at the intersection of critical care innovation and advanced biomaterials engineering, driven by renewed clinical demand for alternatives to mechanical ventilation and improved outcomes in severe respiratory failure. Emerging device architectures aim to replicate pulmonary gas exchange with greater biocompatibility and portability, while procedural ecosystems adapt to integrate extracorporeal support earlier in the care pathway. As attention shifts from acute, in-hospital use toward ambulatory and home-support potential, developers and providers must reconcile intensive-care-grade performance with user-centric design and long-term safety profiles.

Concurrent advances in membrane technologies, pump miniaturization, and sensor-driven control systems are enabling more efficient extracorporeal platforms and nascent implantable solutions that could redefine chronic respiratory support. Regulatory frameworks and clinical evidence requirements are evolving to address these hybrid technologies, increasing the emphasis on real-world performance and human factors. Investors, supply chain partners, and clinical stakeholders are therefore tasked with navigating a highly technical landscape where translational research, manufacturability, and post-market surveillance are equally determinative of commercial success.

In this context, organizations should prioritize cross-disciplinary collaboration spanning materials science, critical care medicine, and regulatory strategy. By aligning technological roadmaps with clinical workflows and reimbursement realities, stakeholders can better bridge proof-of-concept milestones and sustainable adoption pathways for next-generation artificial lung systems.

How materials breakthroughs, miniaturization of support systems, and shifting care delivery models are jointly redefining pathways for artificial lung adoption and integration

Transformative shifts are reshaping the development and deployment of artificial lung technologies as clinical teams demand devices that deliver consistent gas exchange while minimizing thrombogenicity and inflammatory activation. Membrane material innovations are replacing legacy polymers with higher-performance ceramics and engineered hollow fibers, enhancing durability and hemocompatibility. At the same time, the miniaturization of drive consoles and the refinement of hemodynamic management algorithms are enabling more flexible deployment models, including mobile extracorporeal units and potential implantable constructs that are designed for longer-term support.

The clinical landscape is also changing in terms of care setting and stakeholder expectations. There is growing interest in extending extracorporeal support beyond intensive care units to pre-hospital emergency transport and ambulatory settings, which requires ruggedized devices, simplified interfaces, and telemonitoring capabilities. Concurrently, payer and procurement stakeholders are scrutinizing total cost of care and comparative effectiveness, pushing manufacturers to demonstrate not only technical superiority but also operational viability and clear pathways to reimbursement. These intersecting forces are producing a market environment where technological differentiation, clinical integration, and value demonstration are decisive for adoption trajectories.

Assessing the structural and operational consequences of escalated import duties in 2025 on supply chain resilience, sourcing strategies, and product development timelines

The imposition of new tariff regimes and trade measures in 2025 has introduced measurable friction across the supply chains that support artificial lung manufacturing and distribution. Increased duties on key imported components such as precision pumps, specialty membranes, and biocompatible polymers have elevated landed costs for assemblers that rely on cross-border sourcing. As a result, procurement teams and manufacturing planners are reassessing supplier concentration, hedging strategies, and contractual terms to preserve margin and continuity of supply.

Tariff-driven cost pressures have a cascading effect on product development timelines and commercial models. Engineering teams are under pressure to qualify alternative materials and suppliers more rapidly, while quality assurance functions must accelerate validation activities to maintain regulatory compliance. At the distribution level, channel partners are renegotiating pricing structures and service agreements to reflect higher input costs. Moreover, increased import duties are incentivizing nearshoring and regional manufacturing footprints, prompting capital allocation decisions to favor production sites closer to end markets to mitigate tariff exposure.

These dynamics also affect long-term strategic planning, as organizations balance the immediate need to absorb or pass through incremental costs with the broader objective of securing resilient supply chains. Stakeholders that proactively diversify supplier networks, invest in local manufacturing capability, and optimize product design for modularity are better positioned to manage tariff volatility while preserving access to critical components and technologies.

Actionable segmentation insights that connect product architecture, membrane technologies, end-user workflows, application scenarios, distribution approaches, and material selections to commercialization strategies

Understanding segmentation across product, technology, end user, application, distribution channel, and material type is essential for mapping value creation in the artificial lung domain. Product differentiation spans extracorporeal membrane oxygenation systems and investigational implantable artificial lungs, with extracorporeal systems further decomposed into cannula, consoles, oxygenators, and pumps that together determine procedural complexity and footprint. Technology choices range from ceramic and flat sheet membranes to hollow fiber configurations, and within hollow fibers, distinctions between polyethersulfone and polypropylene formulations inform trade-offs in permeability, durability, and hemocompatibility.

End users encompass ambulatory care centers, home care programs, and hospitals, each presenting distinct clinical workflows, staffing models, and procurement cycles that influence product requirements and support expectations. Applications vary across critical care, emergency transport, and respiratory support, and these use cases place different demands on device portability, setup time, and monitoring capabilities. Distribution channels include direct sales, distributor networks, and online platforms; direct sales models often target clinic and hospital accounts with integrated service offerings, while distributor relationships may leverage medical device and pharmaceutical distribution expertise to broaden market presence. Material selection, including polyethersulfone, polypropylene, and silicone, intersects with technology choice and device architecture to shape biocompatibility, sterilization pathways, and component longevity.

Taken together, these segmentation layers create a matrix of requirements that manufacturers must navigate. Product teams should align design specifications to the dominant combinations of technology, material, and end-user needs in their target geographies, while commercial teams should tailor channel strategies and service propositions to match the operational realities of hospitals, ambulatory centers, and home-based care providers.

Regional strategic imperatives that reconcile regulatory variation, clinical infrastructure, and manufacturing footprints to accelerate adoption of artificial lung technologies across global markets

Regional dynamics exert a powerful influence on regulatory expectations, reimbursement practices, and manufacturing logistics across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, clinical research networks and critical care infrastructure support advanced extracorporeal therapies, but market entry and scaling require navigation of diverse payer systems and hospital procurement protocols. Meanwhile, Europe, Middle East & Africa present a complex regulatory mosaic where harmonization efforts coexist with country-specific assessment criteria and procurement norms that shape deployment timelines and clinical evidence requirements.

Asia-Pacific markets demonstrate a spectrum of readiness, from high-volume, innovation-forward centers to regions prioritizing cost-effective and scalable solutions. Manufacturing capacity and supplier ecosystems in Asia-Pacific can offer competitive advantages for component sourcing, yet quality system alignment with international regulatory standards remains a critical gating factor. Across all regions, logistics, tariffs, and local clinical practice patterns inform decisions about regional production hubs, inventory positioning, and support infrastructure. Successful regional strategies integrate regulatory intelligence, localized clinical partnerships, and adaptive pricing models to align product value propositions with payer expectations and care delivery realities.

Organizations planning global rollouts should adopt a region-sensitive approach that sequences regulatory submissions, clinical engagements, and supply chain investments to reflect local priorities and operational constraints. This calibrated strategy reduces commercialization friction and accelerates meaningful clinical adoption across heterogeneous markets.

Key company patterns and competitive imperatives that prioritize membrane innovation, manufacturing rigor, clinical evidence generation, and channel orchestration for durable differentiation

Competitive dynamics in the artificial lung space are shaped by a mix of established medical device manufacturers, specialized component suppliers, and clinical innovators translating translational research into commercial prototypes. Key players invest in membrane science, pump efficiency, and integrated sensor systems to differentiate on performance, ease of use, and lifecycle costs. Strategic partnerships between device OEMs and materials specialists are increasingly common, enabling co-development of membrane structures and hemo-compatible coatings that reduce clot formation and inflammatory responses.

Beyond product innovation, companies that excel in commercialization are the ones that build robust clinical evidence generation programs and engage early with health technology assessment bodies. Manufacturing excellence and quality systems are equally critical; suppliers that can demonstrate scalable, reproducible production of membrane modules and precision pumps secure durable competitive advantages. Channel strategy also matters-organizations that combine direct clinical engagement with selective distributor relationships and digital platforms can extend reach while maintaining control over key customer interactions. Finally, leadership teams that prioritize post-market surveillance and iterative design improvements create a virtuous cycle of safety enhancements and clinician trust, which is especially important for devices that interface directly with blood and respiratory physiology.

High-impact recommendations for leaders to align modular engineering, supplier diversification, clinical evidence programs, and tailored commercial models to drive adoption and resilience

Industry leaders should pursue an integrated agenda that simultaneously addresses technological refinement, supply chain resilience, and clinical adoption pathways. Prioritizing modular device architectures will accelerate qualification of alternative suppliers and support iterative product updates without wholesale platform redesign. Investments in membrane and coating technologies should be coupled with rigorous hemocompatibility testing and human factors engineering to reduce adverse events and simplify clinician workflows. On the supply chain front, diversifying component sources and exploring regional manufacturing nodes can mitigate tariff exposure and logistical disruption while shortening lead times for critical assemblies.

Commercially, organizations should align go-to-market models to end-user needs by tailoring service bundles for hospitals, ambulatory centers, and home care settings, and by building training and remote-monitoring capabilities that lower barriers to adoption. Regulatory strategy must be proactive, embedding post-market data strategies and health economic modeling into submissions to demonstrate clinical utility and value to payers. Finally, leadership should institutionalize scenario-based planning to stress-test product roadmaps against policy shifts, supply interruptions, and payer behavior changes. These parallel actions will strengthen an organization's ability to convert engineering innovation into reliable, widely adopted clinical solutions.

A transparent, evidence-driven methodology integrating clinician interviews, materials and device analyses, supply chain mapping, and scenario testing to inform strategic decision-making

The research approach combines a multi-source evidence base, qualitative expert interviews, and structured analysis to create a comprehensive view of the artificial lung landscape. Primary inputs include discussions with clinicians, biomedical engineers, regulatory advisers, and procurement specialists to capture clinical workflows, device performance priorities, and real-world adoption barriers. Secondary research encompasses peer-reviewed literature, regulatory guidance documents, patents, and manufacturer technical specifications to triangulate technological trends and materials science advances. Comparative analysis of device architectures and supply chain footprints supports assessments of manufacturability and logistical risk.

Analytical methods include technology mapping to compare membrane types and pump platforms, value-chain decomposition to highlight cost and quality drivers, and scenario analysis to anticipate operational responses to policy shifts and tariff changes. Quality control measures include cross-validation of claims with multiple independent sources and critical appraisal of evidence quality for clinical outcomes. The methodology emphasizes transparency in assumptions and traceability of data sources while refraining from projecting numerical market estimates. This layered approach ensures the findings are grounded in empirical evidence and stakeholder perspectives, supporting actionable insights for developers, payers, and providers.

A conclusive synthesis that ties material science breakthroughs, device portability, regulatory alignment, and supply chain resilience into pragmatic pathways for clinical adoption and commercialization

In conclusion, advances in membrane materials, device miniaturization, and systems integration are converging to create an inflection point in artificial lung technologies, with implications for clinical practice, supply chain design, and commercialization strategies. The movement from exclusively in-hospital use toward ambulatory and potentially implantable applications requires a holistic approach that aligns engineering innovation with clinician workflows, regulatory compliance, and payer value assessment. Tariff dynamics and regional manufacturing considerations further underscore the need for resilient sourcing and near-market production options.

Stakeholders that adopt a segmented, regionally aware strategy-one that synchronizes product design, channel approach, and evidence generation-will be better positioned to navigate the complex path from prototype to clinical standard of care. Ultimately, the organizations most likely to succeed will be those that combine technical excellence in membrane and pump systems with disciplined commercialization practices, robust quality systems, and an adaptive supply chain capable of responding to policy and market shocks. This integrated posture will accelerate the translation of technological promise into tangible clinical benefits for patients with severe respiratory insufficiency.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of wearable extracorporeal membrane oxygenation systems into home care settings
  • 5.2. Advancements in 3d printed alveolar scaffolds for personalized artificial lung therapies
  • 5.3. Development of biocompatible polymer membranes for long term artificial lung implants
  • 5.4. Adoption of modular artificial lung devices to support pediatric patients with chronic respiratory failure
  • 5.5. Emergence of portable artificial lung systems validated in ambulatory patient clinical trials
  • 5.6. Regulatory pathways for accelerated approval of artificial lung devices under breakthrough designations
  • 5.7. Collaborations between biotech firms and academic centers to create bioengineered lung tissue constructs

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Artificial Lung Market, by Product Type

  • 8.1. Extracorporeal Membrane Oxygenation System
    • 8.1.1. Cannula
    • 8.1.2. Console
    • 8.1.3. Oxygenator
    • 8.1.4. Pump
  • 8.2. Implantable Artificial Lung

9. Artificial Lung Market, by Technology

  • 9.1. Ceramic Membrane
  • 9.2. Flat Sheet Membrane
  • 9.3. Hollow Fiber Membrane
    • 9.3.1. Polyethersulfone
    • 9.3.2. Polypropylene

10. Artificial Lung Market, by End User

  • 10.1. Ambulatory Care Centers
  • 10.2. Home Care
  • 10.3. Hospitals

11. Artificial Lung Market, by Application

  • 11.1. Critical Care
  • 11.2. Emergency Transport
  • 11.3. Respiratory Support

12. Artificial Lung Market, by Distribution Channel

  • 12.1. Direct Sales
    • 12.1.1. Clinic Accounts
    • 12.1.2. Hospital Accounts
  • 12.2. Distributor Network
    • 12.2.1. Medical Device Distributors
    • 12.2.2. Pharmaceutical Distributors
  • 12.3. Online Platforms

13. Artificial Lung Market, by Material Type

  • 13.1. Polyethersulfone
  • 13.2. Polypropylene
  • 13.3. Silicone

14. Artificial Lung Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Artificial Lung Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Artificial Lung Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Getinge AB
    • 17.3.2. LivaNova PLC
    • 17.3.3. Medtronic PLC
    • 17.3.4. Terumo Corporation
    • 17.3.5. Fresenius Medical Care AG & Co. KGaA
    • 17.3.6. MC3 Cardiopulmonary Support Inc.
    • 17.3.7. SynCardia Systems, LLC
    • 17.3.8. ALung Technologies, Inc.
    • 17.3.9. Aeson Cardiovascular AG
    • 17.3.10. Hemovent GmbH

LIST OF FIGURES

  • FIGURE 1. GLOBAL ARTIFICIAL LUNG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. ARTIFICIAL LUNG MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. ARTIFICIAL LUNG MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ARTIFICIAL LUNG MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ARTIFICIAL LUNG MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ARTIFICIAL LUNG MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CANNULA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CANNULA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CANNULA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CANNULA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CANNULA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CANNULA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CONSOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CONSOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CONSOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CONSOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CONSOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CONSOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY OXYGENATOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY OXYGENATOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY OXYGENATOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY OXYGENATOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY OXYGENATOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY OXYGENATOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY PUMP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY PUMP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY PUMP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY PUMP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY PUMP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY PUMP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY IMPLANTABLE ARTIFICIAL LUNG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY IMPLANTABLE ARTIFICIAL LUNG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY IMPLANTABLE ARTIFICIAL LUNG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY IMPLANTABLE ARTIFICIAL LUNG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY IMPLANTABLE ARTIFICIAL LUNG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY IMPLANTABLE ARTIFICIAL LUNG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CERAMIC MEMBRANE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CERAMIC MEMBRANE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CERAMIC MEMBRANE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CERAMIC MEMBRANE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CERAMIC MEMBRANE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CERAMIC MEMBRANE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY FLAT SHEET MEMBRANE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY FLAT SHEET MEMBRANE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY FLAT SHEET MEMBRANE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY FLAT SHEET MEMBRANE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY FLAT SHEET MEMBRANE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY FLAT SHEET MEMBRANE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYETHERSULFONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYETHERSULFONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYETHERSULFONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYETHERSULFONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYETHERSULFONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYETHERSULFONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYPROPYLENE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYPROPYLENE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYPROPYLENE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYPROPYLENE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYPROPYLENE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYPROPYLENE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CRITICAL CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CRITICAL CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CRITICAL CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CRITICAL CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CRITICAL CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CRITICAL CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY EMERGENCY TRANSPORT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY EMERGENCY TRANSPORT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY EMERGENCY TRANSPORT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY EMERGENCY TRANSPORT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY EMERGENCY TRANSPORT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY EMERGENCY TRANSPORT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY RESPIRATORY SUPPORT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY RESPIRATORY SUPPORT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY RESPIRATORY SUPPORT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY RESPIRATORY SUPPORT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY RESPIRATORY SUPPORT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY RESPIRATORY SUPPORT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CLINIC ACCOUNTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CLINIC ACCOUNTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CLINIC ACCOUNTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CLINIC ACCOUNTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CLINIC ACCOUNTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CLINIC ACCOUNTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOSPITAL ACCOUNTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOSPITAL ACCOUNTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOSPITAL ACCOUNTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOSPITAL ACCOUNTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOSPITAL ACCOUNTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOSPITAL ACCOUNTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY MEDICAL DEVICE DISTRIBUTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY MEDICAL DEVICE DISTRIBUTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY MEDICAL DEVICE DISTRIBUTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY MEDICAL DEVICE DISTRIBUTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY MEDICAL DEVICE DISTRIBUTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY MEDICAL DEVICE DISTRIBUTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY PHARMACEUTICAL DISTRIBUTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY PHARMACEUTICAL DISTRIBUTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY PHARMACEUTICAL DISTRIBUTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY PHARMACEUTICAL DISTRIBUTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY PHARMACEUTICAL DISTRIBUTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY PHARMACEUTICAL DISTRIBUTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY ONLINE PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY ONLINE PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY ONLINE PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY ONLINE PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY ONLINE PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY ONLINE PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYETHERSULFONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYETHERSULFONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYETHERSULFONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYETHERSULFONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYETHERSULFONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYETHERSULFONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYPROPYLENE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYPROPYLENE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYPROPYLENE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYPROPYLENE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYPROPYLENE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYPROPYLENE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY SILICONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY SILICONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY SILICONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY SILICONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY SILICONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY SILICONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 303. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 304. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 305. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 306. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 307. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2018-2024 (USD MILLION)
  • TABLE 308. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2025-2032 (USD MILLION)
  • TABLE 309. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 310. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 311. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 312. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 313. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 314. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 315. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2018-2024 (USD MILLION)
  • TABLE 316. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2025-2032 (USD MILLION)
  • TABLE 317. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2018-2024 (USD MILLION)
  • TABLE 318. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2025-2032 (USD MILLION)
  • TABLE 319. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 320. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 321. AFRICA ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 322. AFRICA ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 323. AFRICA ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 324. AFRICA ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 325. AFRICA ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 326. AFRICA ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 327. AFRICA ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 328. AFRICA ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)

TA